Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00060242 · ClinicalTrials.gov registry record · Phase 2

Combretastatin A4 Phosphate in Treating Patients With Advanced Anaplastic Thyroid Cancer

A Phase 2 study of Head and Neck Cancer, sponsored by Case Comprehensive Cancer Center.

Completed
Registry status
Phase 2
Development phase
26
Enrollment target
3
Study locations

NCT00060242: Completed Phase 2 study of Head and Neck Cancer, sponsored by Case Comprehensive Cancer Center.

NCT00060242 is a Phase 2 study of Head and Neck Cancer that has completed, run by Case Comprehensive Cancer Center. The registered enrollment target is 26 participants, below the 261-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (90% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00060242, a Phase 2 study of Head and Neck Cancer, has completed, sponsored by Case Comprehensive Cancer Center.

COMPLETED
Registry status
Phase 2
Development phase
26 participants
Enrollment target
3
Study locations

Study Summary

RATIONALE: Combretastatin A4 phosphate may stop the growth of anaplastic thyroid cancer by stopping blood flow to the tumor. PURPOSE: This phase II trial is studying how well combretastatin A4 phosphate works in treating patients with advanced recurrent or metastatic anaplastic thyroid cancer.

Conditions Studied

Head and Neck Cancer

Interventions

  • DRUG fosbretabulin disodium

Study Locations (3)

Michigan

  • Josephine Ford Cancer Center at Henry Ford Hospital - Detroit

Ohio

  • Ireland Cancer Center at University Hosptials Case Medical Center, Case Comprehensive Cancer Center - Cleveland

Pennsylvania

  • Hillman Cancer Center at University of Pittsburgh Cancer Institute - Pittsburgh

Trial Details

FieldValue
Enrollment Target 26 participants
Start Date 2003-02
Est. Completion 2008-01
Phase Phase 2
Case Comprehensive Cancer Center

407 total trials

What the finished NCT00060242 record still lists

NCT00060242 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 26 participants, a relatively small participant target, below the 261-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (90% lower).

The record links to 1 condition, with Head and Neck Cancer appearing as the primary indexed condition, and to 1 intervention - of which fosbretabulin disodium is the first listed.

NCT00060242 reports a single indexed study location in Michigan, Ohio, Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT00060242 about?

NCT00060242 is a clinical study titled "Combretastatin A4 Phosphate in Treating Patients With Advanced Anaplastic Thyroid Cancer". RATIONALE: Combretastatin A4 phosphate may stop the growth of anaplastic thyroid cancer by stopping blood flow to the tumor. PURPOSE: This phase II trial is studying how well combretastatin A4 phosphate works in treating patients with advanced recurrent or metastatic anaplastic thyroid cancer.

What is the current status of trial NCT00060242?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 26 participants. The study started on 2003-02. Estimated completion is 2008-01.

What conditions does trial NCT00060242 study?

This clinical trial studies the following conditions: Head and Neck Cancer.

What interventions are being tested in trial NCT00060242?

The interventions under investigation include: fosbretabulin disodium (DRUG).

Who is sponsoring clinical trial NCT00060242?

This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00060242 being conducted?

This trial has 3 study locations across Michigan, Ohio, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Head and Neck Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00060242's enrollment target sits among peer trials

26 193rd of 250 higher than 56 of 250 other Head and Neck Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Head and Neck Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02646475 · 26 participants · Phase 1

    Metabolic Effects of Angiotensin-(1-7)

  • NCT03603223 · 26 participants · Phase 2

    Pembrolizumab in Treating Participants With Leukoplakia

  • NCT04063592 · 26 participants · NA

    AMI Construction in Lower Extremity Residual Limbs

  • NCT04906460 · 26 participants · Phase 1

    Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT00060242, the US trial registry maintained by the National Library of Medicine. NCT00060242 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.